Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2968544 | 0.85 | ALDH1A1 (0.41) | KMT2AMEN1RAB9ACES2CES1 | |
| SCHEMBL21470599 | 0.83 | CYP1A2 (0.46) | KMT2AMEN1CYP1A2CYP2C19CES2 | |
| SCHEMBL7639135 | 0.78 | GRM2 (0.39) | KMT2AMEN1RAB9ACES2CES1 | |
| SCHEMBL25571225 | 0.76 | RECQL (0.40) | KMT2AMEN1RAB9ACYP1A2CYP2C19 | |
| SCHEMBL210873 | 0.74 | CA1 (0.53) | KMT2AMEN1RAB9ACYP1A2CES2 | |
| SCHEMBL17148179 | 0.74 | CA1 (0.53) | KMT2AMEN1RAB9ACYP1A2CES2 | |
| SCHEMBL667418 | 0.74 | APP (0.46) | RIPK1NSD2 | |
| SCHEMBL2789271 | 0.73 | AKT1 (0.44) | RAB9ARIPK1ALDH1A1 | |
| Fluorobenzene SCHEMBL7430467 | 0.72 | MAOA (0.40) | KMT2AMEN1RAB9ACYP1A2CYP2C19 | |
| SCHEMBL7430459 | 0.72 | RIPK1 (0.59) | KMT2ARIPK1NSD2HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753392-B2 | Method for synthesis of deuterated amide and deuterated sulfonamide | HINOVA PHARMACEUTICALS INC. (CN) | 2023-09-12 | — | — | US | disclosed |
| US-11753392-B2 | Method for synthesis of deuterated amide and deuterated sulfonamide | HINOVA PHARMACEUTICALS INC. (CN) | 2023-09-12 | — | — | US | disclosed |
| US-20210115009-A1 | METHOD FOR SYNTHESIS OF DEUTERATED AMIDE AND DEUTERATED SULFONAMIDE | HINOVA PHARMACEUTICALS INC. (CN) | 2021-04-22 | — | — | US | disclosed |
| EP-3778538-A1 | NOVEL METHOD FOR SYNTHESIZING DEUTERATED AMIDES AND DEUTERATED SULFONAMIDES | Hinova Pharmaceuticals Inc. (CN) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019196945-A1 | NOVEL METHOD FOR SYNTHESIZING DEUTERATED AMIDES AND DEUTERATED SULFONAMIDES | 成都海创药业有限公司 | 2019-10-17 | — | — | WO | disclosed |
| US-8324212-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120046294-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-23 | — | — | US | disclosed |
| WO-2011106340-A1 | PYRAZOLOPYRIDAZINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115009-A1 | METHOD FOR SYNTHESIS OF DEUTERATED AMIDE AND DEUTERATED SULFONAMIDE | SRM, NAAA, SNRPD2 | KMT2A 196/4885MEN1 527/4885RAB9A 2374/4885 |
| US-20120046294-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | KMT2A 4624/4885MEN1 4676/4885RAB9A 2224/4885 |
| US-11753392-B2 | Method for synthesis of deuterated amide and deuterated sulfonamide | SRM, NAAA, SNRPD2 | KMT2A 196/4885MEN1 527/4885RAB9A 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.